Aclaris Therapeutics (ACRS) Treasury Shares (2014 - 2015)

Aclaris Therapeutics' Treasury Shares history runs 9 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Treasury Shares fell 41.66% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 41.66% YoY), while the FY2025 annual figure was $2.2 million, up 3.99% from the prior year.
• Treasury Shares for Q1 2026 stood at $1.9 million, down from $2.2 million in the prior quarter.
• The five-year high for Treasury Shares was $3.2 million in Q1 2025, with the low at $2375.0 in Q2 2022.
• The 5-year median for Treasury Shares is $1.7 million (2023), against an average of $1.8 million.
• The sharpest annual moves came in 2022 and 2023: Treasury Shares sank 99.84% in 2022, then surged 72322.74% in 2023.
• Aclaris Therapeutics' Treasury Shares stood at $1.5 million in 2022, then climbed by 0.08% to $1.5 million in 2023, then surged by 37.73% to $2.1 million in 2024, then advanced by 3.99% to $2.2 million in 2025, then retreated by 15.04% to $1.9 million in 2026.
• Business Quant data shows ACRS's Treasury Shares at $1.9 million in Q1 2026, $2.2 million in Q4 2025, and $241840.0 in Q3 2025.